Sponsor: Loxo Oncology, Inc.
Disclosed research payments
$2,037,139
Named PIs
5
- RICHY AGAJANIAN: $243,858
- SALEHA SAJID: $165,169
- CHANH HUYNH: $153,966
Leukemia (CLL / AML): drug payment transparency
Chronic lymphocytic leukemia (CLL) treatment has four FDA-approved covalent BTK inhibitors plus a non-covalent option, all with first-line indications. Head-to-head trials exist but they do not cover every clinical scenario. In acute myeloid leukemia, FLT3 and IDH1/IDH2 mutation-directed therapies each have multiple approved options.
Data from CMS Open Payments (2023–2024) · last checked
The drugs in question
These are the close-substitute branded therapies your oncologist may choose among for leukemia (cll / aml). Generic and biosimilar options may also be available depending on line of therapy.
BTK inhibitors (CLL)
- Imbruvica (ibrutinib) — Johnson & Johnson / AbbVie
- Calquence (acalabrutinib) — AstraZeneca
- Brukinsa (zanubrutinib) — BeiGene
- Jaypirca (pirtobrutinib) — Eli Lilly
BCL-2 inhibitors
- Venclexta / Venclyxto (venetoclax) — AbbVie / Roche
FLT3 inhibitors (AML)
- Rydapt (midostaurin) — Novartis
- Xospata (gilteritinib) — Astellas
- Vanflyta (quizartinib) — Daiichi Sankyo
IDH1/IDH2 inhibitors (AML)
- Tibsovo (ivosidenib) — Servier
- Idhifa (enasidenib) — Bristol-Myers Squibb / Servier
- Rezlidhia (olutasidenib) — Rigel
Top paying manufacturers to oncologists in our index
Across all oncologists in our index (all cancer types), these are the companies making these leukemia (cll / aml) drugs, summed across their latest reported year of disclosures. Payments include both general and research categories; see methodology for the split.
| Manufacturer | Total disclosed to oncologists (latest year) |
|---|---|
| AstraZeneca | $11,913,894 |
| Eli Lilly | $6,269,708 |
| AbbVie | $3,665,646 |
| Daiichi Sankyo | $3,153,149 |
| Novartis | $2,644,139 |
| BeiGene | $2,395,730 |
| Astellas | $1,725,342 |
| Roche | $1,694,787 |
leukemia (cll / aml) trials with research-payment cross-reference
Active leukemia (cll / aml) trials in our database where one or more research-payment records (tied to the trial's NCT ID) are disclosed in CMS Open Payments. We show the disclosed principal investigators and amounts. The presence of research payments on a trial is expected — industry-funded clinical trials pay the physicians running them for site work — but knowing the scale gives you useful context.
Sponsor: BeiGene · sponsor also appears in the payment records
Disclosed research payments
$562,326
Named PIs
5
- COURTNEY DINARDO: $208,000
- GURU SUBRAMANIAN GURU MURTHY: $176,919
- JING ZHOU HOU: $72,059
Sponsor: Ossium Health, Inc.
Disclosed research payments
$281,381
Named PIs
5
- SAGAR PATEL: $77,238
- JEREMY PANTIN: $67,376
- UTTAM RAO: $47,300
Sponsor: AbbVie · sponsor also appears in the payment records
Disclosed research payments
$247,582
Named PIs
5
- FARRUKH AWAN: $53,750
- BRUCE CHESON: $51,969
- ARI PELCOVITS: $33,090
Sponsor: Loxo Oncology, Inc.
Disclosed research payments
$137,646
Named PIs
5
- JAMES D'OLIMPIO: $127,194
- BITA FAKHRI: $1,307
- BRUCE CHESON: $1,307
Questions to ask your oncologist
- Among the approved options for my stage and biomarker profile, which do you recommend, and why this one over its close substitutes?
- Have you received consulting, speaking, or research payments from the maker of the drug you're recommending? (Every U.S. physician can look themselves up at openpaymentsdata.cms.gov.)
- Are there cooperative-group or NIH-sponsored trials I should consider, in addition to industry-sponsored ones?
- What do the published head-to-head trials show for the option you're recommending versus its substitutes?
A financial relationship between a physician and a manufacturer is not, on its own, a problem — it is the expected context of modern drug development. The purpose of federal disclosure is to let you ask informed questions, not to make the decision for you.
More on leukemia (cll / aml)
Medical disclaimer: This page aggregates public federal data and is not medical advice. Drug choice for any individual patient depends on stage, biomarker profile, prior therapy, comorbidities, and patient preference — decisions that must be made with your licensed care team.
About the payment data: Figures are disclosed by manufacturers to CMS under the Physician Payments Sunshine Act (42 U.S.C. §1320a-7h). Presence of payments is not a conflict of interest. Physicians who believe a record is wrong file a correction through the CMS dispute process.
Sources: CMS Open Payments · ClinicalTrials.gov · Data fetched: 2026-04-21 · full methodology